CVRx, Inc.

NASDAQ:CVRX

Medical - Devices

Healthcare
$2.63 +2.28%

+$0.11 today

Market cap
$69.79M
Beta
0.77
P/E (TTM)
-2.5
EPS (TTM)
-$2.00
52W Low $4.37High $11.30

Volume 0.37M

Average 0.30M

CVRX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

CVRx, Inc.NASDAQ: CVRX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $205K rose 11.4% year over year, behind the +15.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 10.8% from the prior quarter. Over 3 fiscal years it compounded at +22.4% a year.

Context

  • Depreciation & amortization amounted to 1.3% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +11.4% toward the trailing-twelve-month pace of +15.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$205K+10.8% QoQ
Last fiscal yearDec 2025
$756K+22.1% YoY
LTMMar 2026
$777K+15.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.4%——
1 year+22.1%——
3-year CAGR+22.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
756K USD
Year-over-year change
+22.1%
4-year CAGR
+45.6%

Depreciation & Amortization vs competitors

How CVRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.6% is the 4th highest of 10, against a peer median of +3.1%.
  • Depreciation & amortization amounts to 1.3% of revenue for CVRX, versus a peer median of 7.5%.
CVRX Competitors
Depreciation & Amortization for CVRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VMDViemed Healthcare, Inc.LTM Mar 2026$29.62M USD+15.3%+22.3%10.3%
QTRXQuanterix CorporationLTM Mar 2026$22.58M USD+148.0%+52.4%15.6%
NNOXNano-X Imaging Ltd.LTM Dec 2025$11.7M USD-0.3%+0.5%89.8%
MASS908 Devices Inc.LTM Mar 2026$4.31M USD-7.1%+33.4%7.5%
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.72M EUR-0.9%+1.0%20.3%
CERSCerus CorporationLTM Mar 2026$2M USD+30.3%-14.7%0.9%
SENSSenseonics Holdings, Inc.LTM Mar 2026$1.48M USD+102.1%-54.8%3.6%
CVRXCVRx, Inc.LTM Mar 2026$777K USD+15.6%+22.4%1.3%
SGHTSight Sciences, Inc.LTM Mar 2026$690K USD+3.1%-11.8%0.9%
SNWVSANUWAVE Health, Inc.LTM Mar 2026$103K USD-90.0%+10.5%0.2%
Peer median (excluding CVRX) —+3.1%+1.0%7.5%

Competitors are the stored peer set for CVRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.08M)(41.43M)(41.2M)(59.97M)(53.31M)
Depreciation & Amortization168K412K522K619K756K
Deferred Income Tax14.62M0000
Stock-Based Compensation1.91M3.89M6.3M19.05M11.05M
Change in Working Capital(1.58M)(5.57M)(4.81M)949K1M
Accounts Receivables(1.28M)(2.94M)(2.05M)(1.72M)(1.4M)
Inventory(537K)(3.08M)(4.03M)(1.12M)(98K)
Accounts Payables27K1.21M165K698K1.25M
Other Working Capital207K(761K)1.1M3.09M1.25M
Other Non-Cash Items229K25K158K203K327K
Operating Cash Flow(27.73M)(42.68M)(39.02M)(39.14M)(40.17M)
Capital Expenditures(1.18M)(685K)(591K)(1.36M)(580K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(1.18M)(685K)(591K)(1.36M)(580K)
Debt Repayment(21.3M)7.5M22.5M20M0
Common Stock Issued133.16M771K1.66M32.52M10.52M
Common Stock Repurchased(1K)0000
Dividends Paid00000
Other Financing Activities23K(7K)1.48M3.35M0
Financing Cash Flow111.88M7.49M23.98M55.87M10.52M
Effect of Forex Changes(8K)(9K)3K(1K)5K
Net Change in Cash82.96M(35.88M)(15.63M)15.36M(30.23M)
Free Cash Flow(28.92M)(43.36M)(39.61M)(40.51M)(40.75M)

CVRx, Inc.

NASDAQ:CVRX

Intrinsic Alpha fair value

Locked

Current Price

$2.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.